Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Inflectra's Label Won't Depend On Continuing Study In IBD

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committee members anxious about extrapolating Remicade's inflammatory bowel disease indications to biosimilar Inflectra wanted to wait for an ongoing trial, but FDA says idea misses the point of biosimilar pathway.


Related Content

Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences
How To Label A Biosimilar? Copy The Reference Product, FDA Told Sandoz


Related Companies